Travere Therapeutics (TVTX) Short term Debt (2016 - 2025)
Historic Short term Debt for Travere Therapeutics (TVTX) over the last 13 years, with Q2 2025 value amounting to $68.8 million.
- Travere Therapeutics' Short term Debt changed N/A to $68.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $68.8 million, marking a year-over-year change of. This contributed to the annual value of $68.7 million for FY2024, which is N/A changed from last year.
- Latest data reveals that Travere Therapeutics reported Short term Debt of $68.8 million as of Q2 2025.
- Travere Therapeutics' 5-year Short term Debt high stood at $68.8 million for Q2 2025, and its period low was $6.9 million during Q1 2023.
- Its 5-year average for Short term Debt is $29.6 million, with a median of $7.4 million in 2021.
- Its Short term Debt has fluctuated over the past 5 years, first plummeted by 5747.13% in 2021, then tumbled by 540.54% in 2022.
- Travere Therapeutics' Short term Debt (Quarter) stood at $7.4 million in 2021, then fell by 5.41% to $7.0 million in 2022, then fell by 1.43% to $6.9 million in 2023, then soared by 895.33% to $68.7 million in 2024, then rose by 0.23% to $68.8 million in 2025.
- Its last three reported values are $68.8 million in Q2 2025, $68.8 million for Q1 2025, and $68.7 million during Q4 2024.